Johnson and johnson news

Here are some recent news articles and updates about Johnson & Johnson:

Recent News

  1. J&J to pay $2.1 billion to settle opioid lawsuits: Johnson & Johnson has agreed to pay $2.1 billion to settle thousands of lawsuits alleging that the company's marketing and sales practices contributed to the opioid epidemic. (Source: CNBC, March 2023)
  2. J&J's COVID-19 vaccine gets EU approval: The European Union has approved Johnson & Johnson's COVID-19 vaccine, Ad26.COV2.S, for use in the region. (Source: Reuters, March 2023)
  3. J&J to acquire Momenta Pharmaceuticals: Johnson & Johnson has agreed to acquire Momenta Pharmaceuticals, a biotech company focused on developing treatments for autoimmune diseases. (Source: Bloomberg, February 2023)
  4. J&J's talcum powder lawsuits continue to mount: Johnson & Johnson is facing thousands of lawsuits alleging that its talcum powder products cause ovarian cancer and mesothelioma. (Source: CNN, February 2023)
  5. J&J's COVID-19 vaccine shows promise in clinical trials: Johnson & Johnson's COVID-19 vaccine has shown promising results in clinical trials, with a 66% efficacy rate in preventing severe illness. (Source: The New York Times, January 2023)

Recent Financial News

  1. J&J's quarterly earnings beat expectations: Johnson & Johnson reported stronger-than-expected quarterly earnings, driven by growth in its pharmaceutical and medical devices segments. (Source: MarketWatch, January 2023)
  2. J&J's stock price rises on vaccine hopes: Johnson & Johnson's stock price rose after the company announced positive results from its COVID-19 vaccine clinical trials. (Source: CNBC, December 2022)
  3. J&J's revenue growth slows in Q3: Johnson & Johnson's revenue growth slowed in the third quarter, due in part to declining sales of its consumer products. (Source: The Wall Street Journal, October 2022)

Recent Product News

  1. J&J launches new COVID-19 vaccine booster: Johnson & Johnson has launched a new COVID-19 vaccine booster, designed to provide longer-lasting protection against the virus. (Source: Forbes, February 2023)
  2. J&J's Stelara approved for psoriasis treatment: The US FDA has approved Johnson & Johnson's Stelara (ustekinumab) for the treatment of moderate to severe plaque psoriasis. (Source: Medical News Today, January 2023)
  3. J&J's Xarelto approved for stroke prevention: The US FDA has approved Johnson & Johnson's Xarelto (rivaroxaban) for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation. (Source: Medscape, December 2022)